- Home
- VYGR vs SPOK Comparison
VYGR vs SPOK Comparison
Compare VYGR & SPOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- SPOK
- Stock Information
- Founded
- VYGR 2013
- SPOK 2004
- Country
- VYGR United States
- SPOK United States
- Employees
- VYGR N/A
- SPOK N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- SPOK Telecommunications Equipment
- Sector
- VYGR Health Care
- SPOK Telecommunications
- Exchange
- VYGR Nasdaq
- SPOK Nasdaq
- Market Cap
- VYGR 386.1M
- SPOK 315.5M
- IPO Year
- VYGR 2015
- SPOK 1992
- Fundamental
- Price
- VYGR $5.66
- SPOK $16.22
- Analyst Decision
- VYGR Strong Buy
- SPOK Hold
- Analyst Count
- VYGR 8
- SPOK 1
- Target Price
- VYGR $17.00
- SPOK $15.00
- AVG Volume (30 Days)
- VYGR 590.4K
- SPOK 126.0K
- Earning Date
- VYGR 11-12-2024
- SPOK 10-30-2024
- Dividend Yield
- VYGR N/A
- SPOK 7.72%
- EPS Growth
- VYGR N/A
- SPOK N/A
- EPS
- VYGR 0.47
- SPOK 0.71
- Revenue
- VYGR $163,784,000.00
- SPOK $137,714,000.00
- Revenue This Year
- VYGR N/A
- SPOK $2.45
- Revenue Next Year
- VYGR N/A
- SPOK $0.80
- P/E Ratio
- VYGR $12.13
- SPOK $22.84
- Revenue Growth
- VYGR 3.40
- SPOK N/A
- 52 Week Low
- VYGR $5.19
- SPOK $13.24
- 52 Week High
- VYGR $11.72
- SPOK $18.14
- Technical
- Relative Strength Index (RSI)
- VYGR 38.70
- SPOK 55.72
- Support Level
- VYGR $5.19
- SPOK $15.75
- Resistance Level
- VYGR $5.59
- SPOK $16.25
- Average True Range (ATR)
- VYGR 0.39
- SPOK 0.37
- MACD
- VYGR -0.15
- SPOK -0.09
- Stochastic Oscillator
- VYGR 20.76
- SPOK 34.93
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise. The company provides paging services and software solutions in the United States and abroad. It provides services such as Value-Added Services, Advisory Services, Assessment Services and Adoption Services.